ClinicalTrials.gg
TerminatedNCT01615211Updated May 18, 2015

Randomized Study of Letrozole and Trilostane for Medical Abortion

A Phase 2 interventional study of Letrozole and Trilostane in Medical Abortion, Complete or Unspecified, Without Complication, sponsored by Kristina Gemzell Danielsson. Terminated at 1 site in Sweden. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2015-05-18.

Sponsored by Kristina Gemzell Danielsson · Phase 2, Interventional, and Treatment

Why this study was terminated
No access to study drug Trilostan. Company closed down
Phase
Phase 2
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Study summary

In menstruation an effective shedding of the endometrial lining occurs. Both progesterone and estrogen levels fall sharply at this time. During medical abortion the endometrial shedding is sometimes ineffective causing an incomplete abortion which may cause prolonged bleeding or require surgical intervention. In medical abortion a progesterone antagonist is used as treatment but the estrogen levels are not targeted. The investigators wish to explore whether addition of letrozole or trilostane which target estrogen levels can lead to a more effective shedding of the endometrial lining.

02

Conditions studied

  • Medical Abortion, Complete or Unspecified, Without Complication

Keywords

  • Abortion
  • medical abortion
  • termination of pregnancy
  • Mifepristone
  • misoprostol
  • letrozole
  • trilostane
  • femara
  • Modrenal
03

In context

Lead sponsor

Kristina Gemzell Danielsson is the lead sponsor of 5 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy women aged 18-45 without any for treatment of any of the drugs involved in teh study

Exclusion criteria

Exclusion Criteria:

  • Any ongoing medication or medical condition smoking >20 cigarettes per day >30
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
36 participants (estimated)

Study arms

  • No intervention
    Standard treatment

    patients will receive standard treatment with 200mg Mifepristone and after 36-48 hours 800 mcg of misoprostol vaginally

  • Active comparator
    trilostane

    patients will receive Day 1: Mifepristone 200 mg and Trilostane 120mg 1 tablet twice and Day 2 Trilostane 240mg twice. On Day 3 800 mcg misoprostol will be given vaginally.

    Drug: Trilostane

  • Active comparator
    Letrozole

    Patients will receive on Day 1 Mifepristone 200mg and Letrozole 2,5mg 3 tablets and on Day 2 Letrozole 2,5mg 3 tablets. On day 3 800mcg of misoprostol will be given vaginally

    Drug: Letrozole

Interventions

  • Day 1 Letrozole 2,5mg 3 tablets Day 2 Letrozole 2,5mg 3 tablets

    Also known as: Brand name Femar

  • DrugTrilostane

    Day 1 Trilostane 120mg twice and Day 2 Trilostane 240mg twice

    Also known as: Brand name Modrenal

06

What researchers measure

Primary outcomes

  1. efficacy

    Evaluation of complete abortion by clinical judgement and ultrasonography

    Time frame: 4 weeks

Secondary outcomes

  1. Acceptability

    questionnaire. Preferred future method of medical abortion.

    Time frame: 1 week, 2 weeks and 4 weeks

07

Study locations

1 site
  • Karolinska University Hospital
    Stockholm, 17177, Sweden
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2012, a primary completion of Oct 2013 and a completion of Oct 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2012
First posted
Jun 8, 2012
Start
May 2012
Primary completionActual
Oct 2013
CompletionActual
Oct 2013
Last update
May 18, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01615211
Lead sponsor
Kristina Gemzell Danielsson
Responsible party
Kristina Gemzell Danielsson (Professor, Karolinska Institutet) — Sponsor-investigator
First posted
Jun 8, 2012
Start date
May 2012
Primary completion
Oct 2013
Completion
Oct 2013
Last update
May 18, 2015

Study contacts

Kristina Gemzell Danielsson, professor
principal investigator · Karolinska Institutet
Helena Kopp Kallner, MD
principal investigator · Karolinska Institutet

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Letrozole

Start the discussion